These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 8320247)

  • 1. Prophylaxis of heart transplant rejection with either antithymocyte globulin-, Minnesota antilymphocyte globulin-, or an OKT3-based protocol.
    Ladowski JS; Dillon T; Schatzlein MH; Peterson AC; Deschner WP; Beatty L; Sullivan M; Scheeringa RH; Clark WR
    J Cardiovasc Surg (Torino); 1993 Apr; 34(2):135-40. PubMed ID: 8320247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antilymphocyte induction immunosuppression in the post-Minnesota anti-lymphocyte globulin era: incidence of renal dysfunction and delayed graft function. A single center experience.
    Malinow L; Walker J; Klassen D; Oldach D; Schweitzer E; Bartlett ST; Weir MR
    Clin Transplant; 1996 Jun; 10(3):237-42. PubMed ID: 8826659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of cadaveric renal transplantation by induction treatment in the cyclosporine era.
    Hariharan S; Alexander JW; Schroeder TJ; First MR
    Clin Transplant; 1996 Apr; 10(2):186-90. PubMed ID: 8664516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact of replacing Minnesota antilymphocyte globulin with ATGAM.
    Lum CT; Umen AJ; Kasiske B; Goerdt P; Heim-Duthoy KL; Andersen RC; Odland MD; Ney AL; Jacobs DM; Rao KV
    Transplantation; 1995 Feb; 59(3):371-6. PubMed ID: 7871567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cadaveric kidney transplantation under prophylactic polyclonal antibody immunosuppression with anti-lymphoblast globulin versus anti-thymocyte globulin.
    Indudhara R; Novick AC; Hodge E; Goormastic M; Papajcik D; Mastroianni B; Cook D
    Urology; 1996 Jun; 47(6):807-12. PubMed ID: 8677568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective randomized study of prophylactic OKT3 versus equine antithymocyte globulin after heart transplantation--increased morbidity with OKT3.
    Macdonald PS; Mundy J; Keogh AM; Chang VP; Spratt PM
    Transplantation; 1993 Jan; 55(1):110-6. PubMed ID: 8380508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective comparison of murine monoclonal CD-3 (OKT3) antibody-based and equine antithymocyte globulin-based rejection prophylaxis in cardiac transplantation. Decreased rejection and less corticosteroid use with OKT3.
    Renlund DG; O'Connell JB; Gilbert EM; Hammond ME; Burton NA; Jones KW; Karwande SV; Doty DB; Menlove RL; Herrick CM
    Transplantation; 1989 Apr; 47(4):599-605. PubMed ID: 2523099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Minnesota antilymphoblast globulin and Upjohn antithymocyte globulin for induction immunosuppression of human renal allografts.
    Pescovitz MD; Book BK; Milgrom ML; Leapman SB; Petersen B; Filo RS
    Surgery; 1994 Oct; 116(4):811-8. PubMed ID: 7940183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic therapy for rejection after cardiac transplantation. A comparison of rabbit antithymocyte globulin and OKT3.
    Kirklin JK; Bourge RC; White-Williams C; Naftel DC; Thomas FT; Thomas JM; Phillips MG
    J Thorac Cardiovasc Surg; 1990 Apr; 99(4):716-24. PubMed ID: 2108282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective randomized trial of OKT3- versus horse antithymocyte globulin-based immunosuppressive prophylaxis in heart transplantation.
    Costanzo-Nordin MR; O'Sullivan EJ; Johnson MR; Winters GL; Pifarre R; Radvany R; Zucker MJ; Scanlon PJ; Robinson JA
    J Heart Transplant; 1990; 9(3 Pt 2):306-15. PubMed ID: 2113094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative trial of immunoprophylaxis with RATG versus OKT3.
    Griffith BP; Kormos RL; Armitage JM; Dummer JS; Hardesty RL
    J Heart Transplant; 1990; 9(3 Pt 2):301-5. PubMed ID: 2113093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed development of obliterative bronchiolitis syndrome with OKT3 after unilateral lung transplantation. A plea for multicenter immunosuppressive trials.
    Ross DJ; Jordan SC; Nathan SD; Kass RM; Koerner SK
    Chest; 1996 Apr; 109(4):870-3. PubMed ID: 8635362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Symptomatic cytomegalovirus infection in renal transplant recipients given either Minnesota antilymphoblast globulin (MALG) or OKT3 for rejection prophylaxis.
    Bailey TC; Powderly WG; Storch GA; Miller SB; Dunkel JD; Woodward RS; Spitznagel E; Hanto DW; Dunagan WC
    Am J Kidney Dis; 1993 Feb; 21(2):196-201. PubMed ID: 8381577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA-DR incompatibility predicts heart transplant rejection independent of immunosuppressive prophylaxis.
    Costanzo-Nordin MR; Fisher SG; O'Sullivan EJ; Johnson M; Heroux A; Kao W; Mullen GM; Radvany R; Robinson J
    J Heart Lung Transplant; 1993; 12(5):779-89. PubMed ID: 8241215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic cytolytic therapy in heart transplantation: monoclonal versus polyclonal antibody therapy.
    Laske A; Gallino A; Schneider J; Bauer EP; Carrel T; Pasic M; von Segesser LK; Turina MI
    J Heart Lung Transplant; 1992; 11(3 Pt 1):557-63. PubMed ID: 1610864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction immunosuppression in kidney transplant recipients older than 60 years of age : safety and efficacy of ATGAM, OKT3 and Simulect.
    Heifets M; Saeed MI; Parikh MH; Sierka D; Kumar MS
    Drugs Aging; 2004; 21(11):747-56. PubMed ID: 15323580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of polyclonal antibody sera for early prophylaxis following cardiac transplantation.
    Bolling SF; Stirling MC; Miska P; Deeb GM
    J Surg Res; 1989 Oct; 47(4):292-6. PubMed ID: 2671502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rabbit antithymocyte globulin. A 10-year experience in cardiac transplantation.
    Copeland JG; Icenogle TB; Williams RJ; Rosado LJ; Butman SM; Vasu MA; Sethi GK; McDonald AN; Klees E; Rhenman MJ
    J Thorac Cardiovasc Surg; 1990 May; 99(5):852-60. PubMed ID: 2329823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective randomized controlled trial of initial immunosuppression with ALG versus OKT3 in recipients of cardiac allografts.
    Menkis AH; Powell AM; Novick RJ; McKenzie FN; Kostuk WJ; Pflugfelder PW; Brown JE; Rochon J; Chow LH; Stiller C
    J Heart Lung Transplant; 1992; 11(3 Pt 1):569-76. PubMed ID: 1610866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients.
    Mariat C; Alamartine E; Diab N; de Filippis JP; Laurent B; Berthoux F
    Transpl Int; 1998; 11(3):231-6. PubMed ID: 9638854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.